Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EACR 2012

7 - 10 Jul 2012

Molecular stratification of breast cancer: reaching the clinic

Prof Carlos Caldas - University of Cambridge, UK

Molecular stratification of breast cancer: reaching the clinic ( Prof Carlos Caldas - University of Cambridge, UK )

Circulating metastasis-initiating cells in breast cancer

Prof Andreas Trumpp - German Cancer Research Centre (DKFZ), Heidelberg, Germany

Circulating metastasis-initiating cells in breast cancer ( Prof Andreas Trumpp - German Cancer Research Centre (DKFZ), Heidelberg, Germany )

The ceRNA Hypothesis and the non-coding revolution in cancer research and...

Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA

The ceRNA Hypothesis and the non-coding revolution in cancer research and therapy ( Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA )

Epithelial mesenchyme transition in cancer cells

Prof Jean-Paul Thiery – Institute of Molecular and Cell Biology, Singapore

Epithelial mesenchyme transition in cancer cells ( Prof Jean-Paul Thiery – Institute of Molecular and Cell Biology, Singapore )

Australia Pancreatic Cancer Genome Initiative

Dr Marina Pajic – The Garvan Institute of Medical Research, Darlinghurst...

Australia Pancreatic Cancer Genome Initiative ( Dr Marina Pajic – The Garvan Institute of Medical Research, Darlinghurst, Australia )

Underlying metabolic pathways in cancer

Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain

Underlying metabolic pathways in cancer ( Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain )

Potential for micro-RNA based cancer treatments

Prof Carlo Croce – Ohio State University, Columbus, USA

Potential for micro-RNA based cancer treatments ( Prof Carlo Croce – Ohio State University, Columbus, USA )

Understanding the mechanisms of breast cancer resistance

Prof Jos Jonkers – Netherlands Cancer Institute, Amsterdam, Netherlands

Understanding the mechanisms of breast cancer resistance ( Prof Jos Jonkers – Netherlands Cancer Institute, Amsterdam, Netherlands )

Translational and tailored, but can we afford it?

Prof Gordon McVie - European Institute of Oncology and ecancer

Translational and tailored, but can we afford it? ( Prof Gordon McVie - European Institute of Oncology and ecancer )

Translational and tailored, but can we afford it?

Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden

Translational and tailored, but can we afford it? ( Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden )

Cost efficiency of targeted therapy

Dr Maria Grazia Daidone - Foundazione IRCCS Istituto Nazionale dei Tumori, Italy

Cost efficiency of targeted therapy ( Dr Maria Grazia Daidone - Foundazione IRCCS Istituto Nazionale dei Tumori, Italy )

Society and money - the cancer conundrum

Prof Richard Sullivan – Kings College, London, UK

Society and money - the cancer conundrum ( Prof Richard Sullivan – Kings College, London, UK )

Translating cancer research to personalised treatment: Can it work?

Prof Joan Seoane – Vall d’Hebron Institute of Oncology, Spain

Translating cancer research to personalised treatment: Can it work? ( Prof Joan Seoane – Vall d’Hebron Institute of Oncology, Spain )

The immuno side of melanoma

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Constructing successful biomarker clinical trials

Dr Lisa McShane – National Cancer Institute, Bethesda, USA

Constructing successful biomarker clinical trials ( Dr Lisa McShane – National Cancer Institute, Bethesda, USA )

Highlights of the 22nd EACR meeting and tackling glioblastoma

Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain

Highlights of the 22nd EACR meeting and tackling glioblastoma ( Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain )

The changing field of drug development

Dr Jonathan Yingling – Oncology Drug Discovery, Eli Lilly

The changing field of drug development ( Dr Jonathan Yingling – Oncology Drug Discovery, Eli Lilly )

Epigenetics of cancer and changes in DNA modification in tumours

Prof Manel Esteller – University of Barcelona, Catalonia, Spain

Epigenetics of cancer and changes in DNA modification in tumours ( Prof Manel Esteller – University of Barcelona, Catalonia, Spain )

More from ecancer